PDF(Pubmed)
Abstract：
Dyslipidemia is a component of metabolic syndrome, having an important role in the carcinogenesis of different tumor types, such as prostate, ovarian, or renal cancer. The number of studies on the predictive potential of the different components of the lipid profile with a predictive potential in breast cancer is quite low. The evaluation of the lipid profile was carried out for the 142 patients who benefited from neoadjuvant therapy (NAC) in order to identify a potential predictive biomarker. The serological sample collection was performed sequentially according to a standardized protocol, pre-NAC, post-NAC and 6 months post-NAC after a 6-h pre-collection fast. We also investigated in the general group the presence or absence of the p53 mutation (TP53) and of the mitotic index ki-67, respectively, in relation to the molecular subtypes. The menopausal status, tumor size, family history, grading, Ki-67, p53 and LN metastases have a predictive nature regarding overall survival (OS) (p < 0.05), while for disease free survival (DFS), only tumor size, tumor grading, Ki-67 > 14, and p53+ are of predictive nature. The genetic and molecular analysis carried out in our group indicates that 71.67% have a Ki-67 score higher than 14%, and 39% of the patients have the positive P53 mutation. The multivariate analysis in the case of patients included in the TNBC subtype showed that the increased tumor volume (p = 0.002) and increased level of HDL (p = 0.004) represent predictive factors for the tumor response rate to NAC. High HDL-C levels before NAC and increased LDL-C levels after NAC were associated with the better treatment response in ER-positive and HER2+ breast cancer patients. Increased HDL-C values and tumor volume represent predictive factors as to the response rate to NAC in the case of patients included in the TNBC subtype. Regarding the ER+ and HER2+ subtypes, increased levels of HDL-C pre-NAC and increased levels of LDL-C post-NAC were associated with a better therapeutic response rate. Tumor grading, Ki-67, p53, and LN metastases have a predictive nature for OS, while tumor size, tumor grading, and Ki-67 > 14, and p53+ are predictive for DFS.
摘要：
血脂异常是代谢综合征的一个组成部分，在不同类型肿瘤的癌变中起重要作用，比如前列腺,卵巢,或者肾癌。关于在乳腺癌中具有预测潜力的脂质分布的不同成分的预测潜力的研究数量相当低。对受益于新辅助疗法(NAC)的142名患者进行脂质分布的评估,以鉴定潜在的预测性生物标志物。根据标准化方案依次进行血清学样品收集，前NAC，NAC后和NAC后6个月，经过6小时的预收集快速。我们还在普通组中分别研究了p53突变（TP53）和有丝分裂指数ki-67的存在或不存在。与分子亚型有关。更年期状态，肿瘤大小,家族史,分级,Ki-67，p53和LN转移对总生存期（OS）具有预测性质（p<0.05），而对于无病生存（DFS），只有肿瘤大小,肿瘤分级,Ki-67>14,且p53+具有预测性质。我们小组进行的遗传和分子分析表明，71.67％的Ki-67得分高于14％，39%的患者P53突变阳性。在包括在TNBC亚型中的患者的情况下的多变量分析显示,增加的肿瘤体积(p=0.002)和增加的HDL水平(p=0.004)代表对NAC的肿瘤反应率的预测因素。NAC前高HDL-C水平和NAC后LDL-C水平升高与ER阳性和HER2+乳腺癌患者更好的治疗反应相关。在包括在TNBC亚型中的患者的情况下,增加的HDL-C值和肿瘤体积代表关于对NAC的响应率的预测因素。关于ER+和HER2+亚型，NAC前HDL-C水平升高和NAC后LDL-C水平升高与更好的治疗应答率相关.肿瘤分级,Ki-67、p53和LN转移对OS具有预测性质，虽然肿瘤大小，肿瘤分级,Ki-67>14，p53+可预测DFS。
